Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 5/20 | 0.74 |
| ▸ | DCUN1D1 | Q96GG9 | 13/20 | 0.69 |
| ▸ | UBE2M | P61081 | 11/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18640409 | 1.00 | EPHX2 (0.74) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL3345435 | 0.85 | EPHX2 (1.00) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL13768756 | 0.83 | EPHX2 (0.83) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL11417956 | 0.83 | EPHX2 (0.87) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL18657530 | 0.83 | EPHX2 (0.70) | EPHX2DCUN1D1UBE2MKMT2AEPHX1 | |
| SCHEMBL18658205 | 0.83 | EPHX2 (0.79) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL2732185 | 0.83 | EPHX2 (1.00) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL18640301 | 0.82 | DCUN1D1 (1.00) | DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL27308576 | 0.81 | EPHX2 (0.65) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL2752512 | 0.81 | EPHX2 (0.97) | EPHX2DCUN1D1UBE2MMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2025-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605373-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | CUL3, CUL1, CUL5 | EPHX2 2986/4885DCUN1D1 10/4885UBE2M 12/4885 |
| US-20250120965-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | EPHX2 3008/4885DCUN1D1 3/4885UBE2M 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.